ThesisZurn Elkay Water Solutions: the story is balanced — Non-residential construction activity, particularly institutional projects (schools, hospitals…
★ Analysts see FY2026 revenue reaching $1.9B — +9.4% growth in a single year.
What Moves the Stock
01Non-residential construction activity, particularly institutional projects (schools, hospitals, airports) where specification products command premium pricing
02Water infrastructure spending driven by federal/state funding (IIJA infrastructure bill allocations for water systems, lead pipe replacement programs)
04Raw material cost inflation (brass, stainless steel, resins) and ability to pass through price increases to contractors
05Commercial real estate renovation cycles as older buildings upgrade plumbing systems for code compliance and water efficiency
06Hygienic & Environmental products (estimated 55-60%): Commercial drains, backflow prevention, grease management systems, water control valves sold to contractors and distributors
07Drinking Water products (estimated 40-45%): Elkay-branded water fountains, bottle filling stations, commercial sinks, residential sinks sold to institutional and residential markets
08Aftermarket parts and service revenue providing recurring revenue stream
growth - 43.4% one-year return and 23.6% net income growth attract momentum investors focused on infrastructure beneficiaries and ESG…
Rising rates negatively impact commercial construction financing and delay institutional building projects…
Watch on earnings: Dodge Momentum Index for institutional building projects (leading indicator for specification product demand), US Census Bureau non-residential construction spending (education, healthcare, public safety categories), Copper and brass commodity prices as proxy for raw material cost pressure.
One Sentence Summary:
Zurn Elkay Water Solutions: the story is balanced — non-residential construction activity, particularly institutional projects (schools, hospitals.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.